Application of Ginseng Astragali Dihuang Soup for the Treatment of Diabetic Nephropathy Based on the State-target Theory
10.11842/wst.20250223005
- VernacularTitle:基于态靶理论应用参芪地黄汤治疗糖尿病肾脏病的探讨
- Author:
Yue ZHANG
1
;
Yanhua LIU
;
Pai ZHANG
;
Hongbao ZHANG
Author Information
1. 长春中医药大学中医学院 长春 130117
- Publication Type:Journal Article
- Keywords:
State-target theory;
Diabetic nephropathy;
Qi and Yin deficiency;
Ginseng Astragali Dihuang soup
- From:
World Science and Technology-Modernization of Traditional Chinese Medicine
2025;27(10):2968-2974
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic kidney disease(DKD)is one of the common microvascular complications in diabetes mellitus patients,with oedema,proteinuria,and continuous decline in renal function as the main clinical manifestations,and traditional Chinese medicine(TCM)believes that diabetic kidney disease is caused by a deficiency of Qi and Yin,which runs through the whole process of the disease.In recent years,academician Tong Xiaolin's theory of"state-target theory"provides new ideas for the treatment of diabetic nephropathy.The"state"is a general term for the overall manifestation of the patient's condition.The overall manifestation of the condition of diabetic kidney disease is a"state of deficiency and impairment"with Qi and Yin deficiency as the key mechanism of the disease.The"target"refers to the specific symptoms of the disease or abnormal examination results,which are the clinical symptoms and abnormal indicators caused by diabetic kidney disease.Ginseng astragali dihuang soup is effective in the treatment of diabetic nephropathy,and the application of this formula based on the theory of state-target can make the therapeutic effect more significant,achieve the therapeutic effect of supporting positive Qi,replenishing the deficiency and benefiting the loss,and improve the clinical symptoms and the abnormal physicochemical indexes of diabetic nephropathy,and the state-target co-adjustment,which can provide a new way of thinking for the diagnosis and treatment of diabetic nephropathy for the clinicians.
